By Nancy Price and Katie Komoroski
With the surge in popularity of the GLP-1 receptor agonists Saxenda (liraglutide injection, Novo Nordisk) and Wegovy (semaglutide injection, Novo Nordisk), and the recent FDA approval of Zepbound (tirzepatide, Eli Lilly), employers are facing difficult decisions about coverage for these weight loss medications.
Although these drugs are effective in assisting patients with weight loss, they are also very expensive for employers to cover, with the average